|
A highlight of PIONEER trial results, released during ADA 2019. This includes:
- PIONEER 2 - Oral semaglutide vs empagliflozin
- PIONEER 3 - Oral semaglutide vs sitagliptin
- PIONEER 4 - Oral semaglutide vs liraglutide
- PIONEER 5 - Oral semaglutide in patients with established kidney disease
- PIONEER 6 - The CVOT for oral semaglutide
Featuring an interview with Professor Steve Bain
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education. |